Response of Enhua pharmaceutical: fentanyl series is not sold to the United States

On December 3, Enhua pharmaceutical released a notice, referring to the discussion on fentanyl products in the Internet media, mentioning the smuggling and abuse of fentanyl substances in the United States and the situation that both China and the United States will pay close attention to and take effective measures to deal with Relevant instructions are as follows: 1 Raw materials and injection of fentanyl citrate and remifentanil hydrochloride for injection (hereinafter referred to as "fentanyl series products") were approved, manufactured and sold in December 2011 and October 2014 respectively At present, the company's fentanyl series products are not exported to any country including the United States 2 In accordance with the United Nations Convention against illicit traffic in narcotic drugs and psychotropic substances of 1988, the National Drug Administration strictly controls the production, import and export of narcotic drugs and psychotropic substances Fentanyl series products of the company belong to the narcotic drugs strictly controlled by the state China's Drug Administration Law and regulations on the administration of narcotic drugs have made comprehensive and systematic provisions on the management of the experimental research, production, trading, use, storage, transportation and other links of this kind of drugs The company has formulated a series of management systems, such as the management of the shipment of specially managed drugs, in accordance with the relevant laws and regulations of the state, to strictly carry out the management of production, storage and sales 3 In 2017, the company's sales revenue of fentanyl series products was about 40 million yuan, accounting for about 1.18% of the company's revenue in 2017 The full text of the announcement is as follows: